Digicann Ventures Inc. is a company focused on opportunities within and outside of the cannabis industry.
The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
Life Sciences
Life Sciences
Element Nutritional Sciences Inc. is a producer, distributor and vendor of consumer packaged nutritional products. Element’s products are widely available, scientifically formulated and clinically proven to help rebuild, restore and rejuvenate muscle.
Empatho Holdings Inc. is a virtual well-being firm focused on a smart solution powered by proprietary PsychAI™ artificial intelligence (AI), that strategically guides users to achieve well-being goals. Empatho provides a data-driven mobile application using advanced technology to engage individuals in the management of their own health, helping individuals become more productive and uncovering potential efficiencies and cost savings for employers.
Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.
EXMceuticals (“EXM”) is a bio-science company that strongly believes in the potential health and wellness benefits of hemp and cannabis. EXM is an emerging player in the market, with the ambition to become one of the world's suppliers of highest-grade cannabis ingredients. EXM is currently creating an industrial-scale, GMP, Pharmaceutical Grade Extraction and Refining facility inside the European Union, near Lisbon Portugal. EXM has an existing and licensed cannabis R&D facility and pilot refinery in Lisbon Portugal. EXM is targeting the B2B marketplace and will supply pure ingredients to the pharmaceutical, medicinal and wellness industry.
FinCanna Capital Corp. (the “Issuer”) has not met the continued listing requirements as set out in CSE Policy 2, Appendix A, section 2A.6.
Pursuant to Policy 3 section 3.5(2), the Issuer may not rely on confidential price protection, nor may the Issuer complete any financing without prior Exchange approval.
In accordance with Policy 3, section 3.5, the .X extension is added to the listed securities of Issuers that the Exchange has deemed to be inactive.
FSD Pharma Inc. is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative and inflammatory disorders. The three licensed drug candidates are LUCID-MS, a new chemical entity targeting Multiple Sclerosis, LUCID-PSYCH, a psychoactive molecule targeting Major Depressive Disorder, and FSD-PEA, an ultra-micronized Palmitoyl ethylamine with a favorable safety profile targeting inflammation.
GABY Inc. is a publicly traded cannabis company, listed on the CSE and OTCQB. By the end of 2022, the company plans to expand to additional retail locations, eventually becoming a dominant player in the California market.
The company’s flagship Mankind Dispensary serves nearly 30,000 shoppers per month, has a robust delivery and curbside pickup program, and stocks more than 700 unique products at any time, including GABY’s Kind Republic flower, prerolls, and extracts.
GABY’s leadership team of retail and cannabis experts curate industry-leading experiences which celebrate cannabis culture, and introduces customers to some of the best cannabis in the world.
By operating an expanding portfolio of brands and dispensaries, GABY is building a consumer-focused ecosystem that keeps shoppers happy, prices accessible, and builds lifelong connections between brands and their consumers.
Gaia Grow Corp. (the “Company”) is a licenced cultivator of industrial hemp. The Company’s business model leverages contract farming to utilize existing farmland and skilled farmers to cultivate industrial hemp, which it then sells to processors to be turned into hemp fibre and cannabidiol oil and concentrates. The Company expects to expand its operations to include retail cannabis stores in British Columbia.
